These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 136058)

  • 1. Regulation of the thrombin time in cirrhosis.
    Braunstein KM; Kinard HB; Hepfer TW; Craig WR; Eurenius K
    Thromb Res; 1976 Oct; 9(4):301-17. PubMed ID: 136058
    [No Abstract]   [Full Text] [Related]  

  • 2. [Diagnostic significance of proteolytic breakdown products of fibrinogen and fibrin].
    Heene DL; Genth K
    Internist (Berl); 1984 Feb; 25(2):93-101. PubMed ID: 6231262
    [No Abstract]   [Full Text] [Related]  

  • 3. Establishing the Transient Mass Balance of Thrombosis: From Tissue Factor to Thrombin to Fibrin Under Venous Flow.
    Zhu S; Chen J; Diamond SL
    Arterioscler Thromb Vasc Biol; 2018 Jul; 38(7):1528-1536. PubMed ID: 29724819
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical significance of fibrotic, haemostatic and endotoxic changes in patients with liver cirrhosis.
    Li CJ; Yang ZH; Lu FG; Shi XL; Liu DL
    Acta Gastroenterol Belg; 2018; 81(3):404-409. PubMed ID: 30350529
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A continuous spectrum of hypercoagulability exists in acute nonlymphoblastic leukemia.
    Sureda A; García Frade LJ; Torrado MC; García Laraña J; García Avello A
    Acta Haematol; 1992; 88(2-3):100-4. PubMed ID: 1281598
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Age-based difference in activation markers of coagulation and fibrinolysis in extracorporeal membrane oxygenation.
    Hundalani SG; Nguyen KT; Soundar E; Kostousov V; Bomgaars L; Moise A; Hui SK; Teruya J
    Pediatr Crit Care Med; 2014 Jun; 15(5):e198-205. PubMed ID: 24614609
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activation of thrombosis and fibrinolysis following brain infarction.
    Kataoka S; Hirose G; Hori A; Shirakawa T; Saigan T
    J Neurol Sci; 2000 Dec; 181(1-2):82-8. PubMed ID: 11099716
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Thrombin activation and increased fibrinolysis in patients with chronic liver disease.
    Páramo JA; Rifón J; Fernández J; Cuesta B; Rocha E
    Blood Coagul Fibrinolysis; 1991 Apr; 2(2):227-30. PubMed ID: 1909901
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fibrin clot structure - pro-fibrinolytic effect of oral contraceptives in apparently healthy women.
    Sidelmann JJ; Kluft C; Krug AH; Winkler U; Jespersen J; Gram JB
    Thromb Haemost; 2017 Apr; 117(4):700-705. PubMed ID: 28150855
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Measurement of fibrinogen and fibrin degradation products in serum by staphylococcal clumping test.
    Hawiger J; Niewiarowski S; Gurewich V; Thomas DP
    J Lab Clin Med; 1970 Jan; 75(1):93-108. PubMed ID: 4243578
    [No Abstract]   [Full Text] [Related]  

  • 11. Diagnosis of pre-disseminated intravascular coagulation stage with hemostatic molecular markers. The Mie DIC Study Group.
    Wada H; Wakita Y; Nakase T; Shimura M; Hiyoyama K; Nagaya S; Mori Y; Deguchi K; Shiku H
    Pol J Pharmacol; 1996; 48(2):225-8. PubMed ID: 9112656
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Disseminated intravascular coagulation in liver cirrhosis: fact or fiction?
    Ben-Ari Z; Osman E; Hutton RA; Burroughs AK
    Am J Gastroenterol; 1999 Oct; 94(10):2977-82. PubMed ID: 10520855
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Progressive antithrombin activity and the concentration of three thrombin inhibitors in liver cirrhosis.
    Boneu B; Sie P; Caranobe C; Cassigneul J; Pascal J
    Thromb Haemost; 1982 Feb; 47(1):78. PubMed ID: 7071809
    [No Abstract]   [Full Text] [Related]  

  • 14. Turnover study of prothrombin, antithrombin III and fibrinogen in patients with liver cirrhosis.
    Saitoh H; Kobayashi N; Maekawa T
    Nihon Ketsueki Gakkai Zasshi; 1986 Sep; 49(6):1263-74. PubMed ID: 3811789
    [No Abstract]   [Full Text] [Related]  

  • 15. [Physiological inhibitors of thrombin and thrombin synthesis].
    Schröer H
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1973; 99(2):212-22. PubMed ID: 4122964
    [No Abstract]   [Full Text] [Related]  

  • 16. Endogenous fibrinolysis in septic patients.
    Voss R; Borkowski G; Reitz D; Ditter H; Matthias FR
    Prog Clin Biol Res; 1989; 308():383-7. PubMed ID: 2506571
    [No Abstract]   [Full Text] [Related]  

  • 17. Increased tissue-type plasminogen activator antigen release is not accompanied by increased systemic fibrinolytic activity in severe neonatal respiratory distress syndrome.
    Brus F; Oetomo SB; Schieving J; Groothuis E; Okken A; van Oeveren W
    Pediatr Res; 1999 Apr; 45(4 Pt 1):588-94. PubMed ID: 10203153
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serial thrombolysis-related changes after thrombolytic therapy with TPA in patients with acute myocardial infarction.
    Ho CH; Wang SP
    Thromb Res; 1990 May; 58(3):331-41. PubMed ID: 1693793
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Human thrombin inhibitors ( 2 -macroglobulin and antithrombin 3) during and after surgical and gynecologic-obstetrical intervention].
    Fischer M
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1972; 98(4):397-407. PubMed ID: 4121333
    [No Abstract]   [Full Text] [Related]  

  • 20. [Thrombogenicity of a new prothrombin complex concentrate].
    Klöcking HP; Klessen C; Jablonowski C; Meerbach W; Dornheim G
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1984; 111(5):645-61. PubMed ID: 6083940
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.